Global Doxorubicin Market Price 2024, Forecast To 2033
8 Mar, 2024
The doxorubicin market has demonstrated robust growth, with its size set to increase from $1.23 billion in 2023 to $1.32 billion in 2024, representing a CAGR of 7.6%. This growth is attributed to advancements in chemotherapy, established oncology treatment standards, clinical efficacy, and physician recommendations. Expected to continue its upward trajectory, the market is forecasted to reach $1.71 billion by 2028, growing at a CAGR of 6.7%. Factors driving this growth include advancements in personalized medicine, targeted drug delivery systems, genomic and biomarker research, and the expansion of precision oncology. Major trends encompass nanotechnology integration, combination therapies, biosimilar market expansion, adjuvant therapy focus, and cardioprotective interventions.
Global Doxorubicin Market Key Driver
The rise in cancer prevalence is fueling the growth of the doxorubicin market. Cancer, characterized by abnormal and uncontrolled cell growth, necessitates effective treatment options like doxorubicin, an antibiotic widely used in chemotherapy. By damaging cancer cells' DNA, doxorubicin helps limit their growth. With 1.8 million new cancer cases diagnosed in 2020 according to the American Cancer Society report, and 1,806,590 new cases recorded by the National Cancer Institute in September 2020, indicating a 43% increase from the previous year, the demand for doxorubicin continues to rise. As cancer diagnoses escalate, so does the need for effective treatment options like doxorubicin, driving the growth of the market.
Get A Free Sample Of The Global Doxorubicin Market ReportGlobal Doxorubicin Market Segments
The doxorubicin market covered in this report is segmented –
1) Drug Formulation:Lyophilized Powder, Doxorubicin Injection
2) Application:Breast Cancer, Kidney Cancer, Liver Cancer, Sarcoma, Ovarian Cancer, Lung Cancer, Leukemia, Multiple Myeloma, Other Applications
3) Distribution Channel:Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
By Geography: The countries covered in the doxorubicin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the doxorubicin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the doxorubicin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Doxorubicin Industry Players
Pfizer Inc.; Johnson and Johnson; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Hospira Inc.; Dr. Reddy’s Laboratories Ltd.; Cipla Limited; Hikma Pharmaceuticals; Mylan Pharmaceuticals Inc.; VHB Life Sciences Limited; Xi'an International Healthcare Factory Co. Ltd.; Accord Healthcare Ltd.; TTY Biopharm Company Limited; Cadila Pharmaceuticals; Neon Laboratories Limited; APP Pharmaceuticals Manufacturing LLC; Sun Pharmaceutical Industries Ltd.; Transo-Pharm Handels GmbH; LGM Pharma; Zhejiang Hisun Pharma; Actavis Pharma; Celon Laboratories Limited; Samarth Life Sciences Pvt. Ltd
Get The Full Global Doxorubicin Market Report
Doxorubicin Market Overview
Doxorubicin is a powerful chemotherapy medication that belongs to a class of drugs known as anthracyclines and works by interfering with the DNA and RNA synthesis in cancer cells, preventing their growth and division. It is used for the chemotherapy treatment of distinct types of cancer.